MedPacto, Inc.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2013-06-19
- Employees
- 63
- Market Cap
- -
- Website
- http://www.medpacto.com
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- MedPacto, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT06219733
- Locations
- 🇰🇷
Yeonsei University Severance Hospital, Seoul, Korea, Republic of
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- MedPacto, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05588648
- Locations
- 🇺🇸
UH Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States
🇰🇷National Cancer Center, Gyeonggi-do, Korea, Republic of
🇰🇷Korea Institute of Radiological & Medical Sciences, Seoul, Korea, Republic of
Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- MedPacto, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04515979
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
- Conditions
- Urothelial Carcinoma RecurrentAdvanced Urothelial Carcinoma
- Interventions
- First Posted Date
- 2019-08-21
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- MedPacto, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04064190
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- MedPacto, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03732274
- Locations
- 🇰🇷
Yeonsei University Hospital, Seoul, Korea, Republic of
🇰🇷ChungBuk national university hospital, Chungju, Korea, Republic of
🇰🇷National Cancer Center, Goyang-si, Korea, Republic of
- Prev
- 1
- 2
- Next